Email Us
Cryoablation For Bone Cancer

Cryoablation For Bone Cancer

Three Key Advantages of Cryoablation in Bone Cancer Treatment(1-3)


  • Effective and Durable Pain Relief

Cryoablation offers rapid, significant, and durable pain relief for patients with bone tumors, particularly those with metastases unresponsive to conventional treatments. It effectively reduces pain intensity, improves quality of life, and lowers dependence on opioid analgesics.


  • Improve local tumor control and reduce complications

With real-time imaging guidance such as CT, cryoablation allows precise targeting of tumors and controlled ice ball formation, achieving extensive tumor necrosis while maximizing protection of surrounding healthy bone and soft tissue. Enhances local tumor control rates with a low incidence of major complications.


  • Activates Immune Effectors and Supports Systemic Anti-Tumor Response

Cryoablation not only directly destroys tumor cells but also activates immune effector cells, inducing a systemic anti-tumor immune response and providing strong support for combination immunotherapy


References

  1. Callstrom MR et al. Cryoablation for Palliation of Painful Bone Metastases: The MOTION Multicenter Study. Radiology, 2021. DOI: 10.1148/radiol.2021203831

  2. Arrigoni F et al. Role of Percutaneous Cryoablation in Bone and Soft Tissue Tumors. Frontiers in Oncology, 2023. DOI: 10.3389/ 

  3. Yashiro T et al. Cryoablation for Malignant Bone and Soft Tissue Tumors: Local Control Rates and Safety. Anticancer Research, 2024. DOI: 10.21873


Cryoablation For Bone Cancer Case Sharing
Case 1
Cryosurgery for bone cancer
Cryosurgery for bone cancer
Case 2
Video: Cryoablation for Bone Cancer
Other Cryoablation Cancer Treatment
Contact Us
Contact Us
Hygea Medical Latest News
Hygea Co-Ablation System for Lung Tumors: Clinical Evidence from a Large Retrospective Study
Hygea Co-Ablation System for Lung Tumors: Clinical Evidence from a Large Retrospective Study
New clinical data published in European Journal of Radiology demonstrate that the Hygea Co-Ablation System is a safe and feasible option for the treatment of malignant lung tumors. In more than 200 tr...
READ MORE
Ablation Plus Continuous Anti–PD-1/PD-L1 Therapy in Advanced NSCLC With Oligo-Residual Disease: The BOOSTER Randomized Phase II Trial
Ablation Plus Continuous Anti–PD-1/PD-L1 Therapy in Advanced NSCLC With Oligo-Residual Disease: The BOOSTER Randomized Phase II Trial
Shuo Yang, et al[Abstract]Treatment strategies for advanced non–small cell lung cancer (NSCLC) patients who develop oligo-residual disease (ORD) after responding to immunotherapy remain undefined. Th...
READ MORE
The first randomized phase II trial evaluating ablation plus immunotherapy in advanced NSCLC with oligo-residual disease
The first randomized phase II trial evaluating ablation plus immunotherapy in advanced NSCLC with oligo-residual disease
The BOOSTER study offers the first prospective evidence that adding local ablation to ongoing anti–PD-1/L1 therapy can improve disease control in advanced NSCLC patients with oligo-residual disease. ...
READ MORE